Moderna (MRNA) is back in focus after Phase 3 data showed its mRNA flu vaccine outperformed standard shots in older adults, ...

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Since 2023, Moderna and Korea University have been developing a new mRNA vaccine for hantavirus. The work has been promising ...

The company confirmed early-stage hantavirus research as a WHO-confirmed outbreak grows, while flu vaccine data published in ...

Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious ...

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...

Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.

The findings arrive after a swirl of regulatory uncertainty surrounding the trivalent (three-strain) vaccine, mRNA-1010.

These efforts are early-stage and ongoing and reflect Moderna’s broader responsibility to develop countermeasures against ...